These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 319219)

  • 1. Bioavailability and activity of topical corticosteroids from a novel drug delivery system, the aerosol quick-break foam.
    Woodford R; Barry BW
    J Pharm Sci; 1977 Jan; 66(1):99-103. PubMed ID: 319219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioavailability of topical steroids.
    Barry BW
    Dermatologica; 1976; 152 Suppl 1():47-65. PubMed ID: 955238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potency ranking of two new topical corticosteroid creams containing 0.1% desonide or 0.05% halometasone utilising the human skin blanching assay.
    Meyer E; Smith EW; Haigh JM; Kanfer I
    Arzneimittelforschung; 1988 Dec; 38(12):1840-3. PubMed ID: 3245859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Objective determination of the bioavailability of dermocorticoids--influence of the formulation.
    Poelman MC; Leveque JL; Le Gall F
    Br J Dermatol; 1984 Jul; 111 Suppl 27():158-62. PubMed ID: 6743548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blanching activities of betamethasone formulations. The effect of dosage form on topical drug availability.
    Smith EW; Meyer E; Haigh JM
    Arzneimittelforschung; 1990 May; 40(5):618-21. PubMed ID: 2383308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Age-dependent differences in the pharmacodynamic effect of topically applied Corticosteroids].
    Koch EM; Ott R; Koehler CO
    Arzneimittelforschung; 1986 Oct; 36(10):1540-4. PubMed ID: 3814215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Onset of the vasoconstrictor effect of diflucortolone valerate, betamethasone valerate, and fluocinolone acetonide ointments applied for varying periods under occlusive dressings.
    Szadurski J; Renz F; Gasser D
    Dermatologica; 1976; 153(4):236-42. PubMed ID: 1017533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative bio-availability of proprietary topical corticosteroid preparations; vasoconstrictor assays on thirty creams and gels.
    Barry BW; Woodford R
    Br J Dermatol; 1974 Sep; 91(3):323-38. PubMed ID: 4611447
    [No Abstract]   [Full Text] [Related]  

  • 9. Bioequivalence (bioavailability) of generic topical corticosteroids.
    Jackson DB; Thompson C; McCormack JR; Guin JD
    J Am Acad Dermatol; 1989 May; 20(5 Pt 1):791-6. PubMed ID: 2715430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel foam vehicle for delivery of topical corticosteroids.
    Huang X; Tanojo H; Lenn J; Deng CH; Krochmal L
    J Am Acad Dermatol; 2005 Jul; 53(1 Suppl 1):S26-38. PubMed ID: 15968261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of different desoximetasone preparations compared to other topical corticosteroids in the vasoconstriction assay.
    Borelli C; Gassmueller J; Fluhr JW; Nietsch KH; Schinzel S; Korting HC
    Skin Pharmacol Physiol; 2008; 21(3):181-7. PubMed ID: 18523415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of bioavailability of topical steroids: non-occluded penetration enhancers under thermodynamic control.
    Bennett SL; Barry BW; Woodford R
    J Pharm Pharmacol; 1985 May; 37(5):298-304. PubMed ID: 2862236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility of measuring the bioavailability of topical betamethasone dipropionate in commercial formulations using drug content in skin and a skin blanching bioassay.
    Pershing LK; Silver BS; Krueger GG; Shah VP; Skelley JP
    Pharm Res; 1992 Jan; 9(1):45-51. PubMed ID: 1589409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of clobetasol propionate 0.05 percent ointment and an optimized betamethasone dipropionate 0.05 percent ointment in the treatment of psoriasis.
    Jacobson C; Cornell RC; Savin RC
    Cutis; 1986 Mar; 37(3):213-4, 216, 218-20. PubMed ID: 3514155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris--A randomized phase II study.
    Koo J; Tyring S; Werschler WP; Bruce S; Olesen M; Villumsen J; Bagel J
    J Dermatolog Treat; 2016; 27(2):120-7. PubMed ID: 26444907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Percutaneous absorption of betamethasone 17-benzoate measured by radioimmunoassay.
    Mizuchi A; Miyachi Y; Tamaki K; Kukita A
    J Invest Dermatol; 1976 Aug; 67(2):279-82. PubMed ID: 781144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of bioavailability of topical steroids: penetration enhancers under occlusion.
    Barry BW; Southwell D; Woodford R
    J Invest Dermatol; 1984 Jan; 82(1):49-52. PubMed ID: 6690630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability and activity of betamethasone 17-benzoate in gel and cream formulations: comparison with proprietary topical corticosteroid preparations in the vasoconstrictor assay.
    Woodford R; Barry BW
    Curr Ther Res Clin Exp; 1974 Apr; 16(4):338-45. PubMed ID: 4208350
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of topical corticosteroids on cell proliferation, cell cycle progression and apoptosis: in vitro comparison on HaCaT.
    Guichard A; Humbert P; Tissot M; Muret P; Courderot-Masuyer C; Viennet C
    Int J Pharm; 2015 Feb; 479(2):422-9. PubMed ID: 25556056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The stability and blanching efficacy of betamethasone-17-valerate in emulsifying ointment.
    Ryatt KS; Feather JW; Mehta A; Dawson JB; Cotterill JA; Swallow R
    Br J Dermatol; 1982 Jul; 107(1):71-6. PubMed ID: 7104209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.